医学临床研究
  2025年5月17日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2022, Vol. 39 Issue (10): 1553-1556    DOI: 10.3969/j.issn.1671-7171.2022.10.031
  论著 本期目录 | 过刊浏览 | 高级检索 |
超声引导下经皮冷冻消融配合全雄激素阻断治疗前列腺癌的临床效果及对患者免疫功能的影响
张鹏飞, 雷毅, 薛菁*
陕西中医药大学第二附属医院,陕西 咸阳 712000
Clinical Effect of Ultrasound Guided Percutaneous Cryoablation Combined with Total Androgen Blockade in the Treatment of Prostate Cancer and its Influence on Patients' Immune Function
ZHANG Peng-fei, LEI Yi, XUE Jing
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang Shaanxi 712000
全文: PDF (1128 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨超声引导下经皮冷冻消融术联合全雄激素阻断治疗前列腺癌的临床效果及对患者免疫功能的影响。【方法】回顾性分析2013年2月至2016年2月本院收治的78例前列腺癌患者的临床资料,根据治疗方案的不同将其分为观察组(n=40)和对照组(n=38)。对照组给予全雄激素阻断治疗,观察组在对照组基础上行超声引导下经皮冷冻消融术治疗。比较两组治疗前、治疗后6个月血清前列腺特异性抗原(PSA)、游离前列腺抗原(fPSA)、人前梯度蛋白2(AGR2)以及免疫功能指标(CD3+、CD4+、CD4+/CD8+)、扩展性前列腺癌复合指数量表(EPIC)评分,并统计术后2年、3年、5年生存情况。【结果】观察组治疗后6个月血清PSA、fPSA、AGR2水平均低于对照组,血清CD3+、CD4+、CD4+/CD8+水平均高于对照组(P<0.05);观察组治疗后6个月EPIC评分均高于对照组(P<0.05)。两组术后2年、3年生存率相比,差异无统计学意义(P>0.05),观察组术后5年生存率高于对照组,差异有统计学意义(P<0.05)。【结论】超声引导下经皮冷冻消融术联合全雄激素阻断治疗前列腺癌可降低血清PSA、fPSA、AGR2水平,可改善患者免疫功能及生活质量,提高生存率,值得临床借鉴。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
张鹏飞
雷毅
薛菁
关键词 前列腺肿瘤冷冻外科手术超声检查雄激素拮抗药    
Abstract:【Objective】 To investigate the clinical effect of ultrasound guided percutaneous cryoablation combined with total androgen blockade in the treatment of prostate cancer and its influence on patients' immune function. 【Methods】 The clinical data of 78 patients with prostate cancer admitted to our hospital from February 2013 to February 2016 were analyzed retrospectively, and they were divided into the observation group (n=40) and the control group (n=38) according to different treatment schemes. The control group was treated with total androgen blockade, and the observation group was treated with ultrasound guided percutaneous cryoablation on the basis of the control group. The serum prostate specific antigen (PSA), free prostate antigen (fPSA), human pregradient protein 2 (AGR2), immune function indicators (CD3+, CD4+, CD4+/CD8+), and expanded prostate cancer composite index (EPIC) scores were compared between the two groups before treatment and 6 months after treatment, and the survival conditions of 2, 3, and 5 years after operation were calculated. 【Results】 The levels of serum PSA, fPSA, AGR2 in the observation group were lower than those in the control group 6 months after treatment, and the levels of serum CD3+, CD4+, CD4+/CD8+ were higher than those in the control group (P<0.05); EPIC scores in the observation group were higher than those in the control group 6 months after treatment (P<0.05). There was no significant difference in the 2-year and 3-year survival rates between the two groups (P>0.05). The 5-year survival rate in the observation group was higher than that in the control group, and the difference was statistically significant (P<0.05). 【Conclusion】 Ultrasound guided percutaneous cryoablation combined with total androgen blockade can reduce the serum PSA, fPSA, AGR2 levels, improve the immune function and quality of life of patients with prostate cancer, and improve the survival rate, which is worthy of clinical reference.
Key wordsProstatic Neoplasms    Cryosurgery    Ultrasonography    Androgen Antagonists
收稿日期: 2021-09-15     
中图分类号:  R737.25  
通讯作者: *E-mail:xj13892980530@163.com   
引用本文:   
张鹏飞, 雷毅, 薛菁. 超声引导下经皮冷冻消融配合全雄激素阻断治疗前列腺癌的临床效果及对患者免疫功能的影响[J]. 医学临床研究, 2022, 39(10): 1553-1556.
ZHANG Peng-fei, LEI Yi, XUE Jing. Clinical Effect of Ultrasound Guided Percutaneous Cryoablation Combined with Total Androgen Blockade in the Treatment of Prostate Cancer and its Influence on Patients' Immune Function. JOURNAL OF CLINICAL RESEARCH, 2022, 39(10): 1553-1556.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.10.031     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I10/1553
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn